Abstract
Saphenous vein graft occlusions have been successfully treated with extended urokinase infusions. We report a case of myocardial infarction complicating this treatment. A review of reported cases suggests that this complication may not be uncommon. The optional drug, dose, and infusion technique for intra-graft lytic therapy has not been determined. The costs, risks, and difficulty of this technique may limit its application.
MeSH terms
-
Aged
-
Angina, Unstable / etiology
-
Coronary Artery Bypass
-
Costs and Cost Analysis
-
Graft Occlusion, Vascular / complications
-
Graft Occlusion, Vascular / drug therapy*
-
Humans
-
Male
-
Myocardial Infarction / chemically induced*
-
Saphenous Vein / transplantation*
-
Thrombolytic Therapy / adverse effects*
-
Thrombolytic Therapy / methods
-
Urokinase-Type Plasminogen Activator / adverse effects*
-
Urokinase-Type Plasminogen Activator / therapeutic use
Substances
-
Urokinase-Type Plasminogen Activator